[Chronic liver disease after treatment of malignancies in children].
Chemotherapy, which has greatly improved the prognosis of children with malignant diseases, is potentially hepatotoxic. Furthermore, there is a risk for viral hepatitis acquired by blood products. In this study we looked for hepatotoxicity and for chronic viral hepatitis during and after chemotherapy in 50 unselected children with malignant diseases. 29 children had been treated for leukemia or lymphoma, 19 for solid tumors, 2 for histiocytosis. All patients had been treated before 1991 and had received blood products not screened for hepatitis C-antibodies. In 18 girls and 32 boys aged 12.3 years (range 6.7-24.5 years) hepatitis B- and hepatitis C-serology and liver function tests were measured during a routine check-up 3.6 years (range 0.5-11.8 years) after the last chemotherapy. Liver function tests during chemotherapy were reviewed retrospectively. During chemotherapy 86% of children showed increased ALT and AST levels, 10% had levels above 500 U/l. At follow up 16 children (32%) had pathological liver function tests, especially slightly increased AST and ALT, 13 of these 16 patients had chronic hepatitis C. In contrast only 2 of 34 patients with normal liver function tests had a viral hepatitis (p = 0.001). Patients with elevation of AST and ALT above 100 U/l during chemotherapy had significantly more often a viral hepatitis than those with normal or slightly elevated aminotransferases. Our study shows that hepatocellular damage is a frequent complication following chemotherapy. However this progresses to chronic liver disease very rarely unless the patient acquired a viral hepatitis. The prevalence of chronic hepatitis C was very high in our patients. As screening of blood products for hepatitis C-antibodies is routinely performed since 1991 this problem is likely to have decreased.
Ballauff
A
A
Kinderklinik, Gesamthochschule Essen.
Krähe
J
J
Jansen
B
B
Ross
R S
RS
Roggendorf
H
H
Havers
W
W
D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000032:analysis; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001219:Aspartate Aminotransferases / Q000032:analysis; D001771:Blood Banks / Q000331:legislation & jurisprudence; D002648:Child; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D015994:Incidence; D008107:Liver Diseases / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology*; D008111:Liver Function Tests; D008297:Male; D009369:Neoplasms / Q000628:therapy*; D065227:Transfusion Reaction
D000970:Antineoplastic Agents; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
Chronische Hepatopathien nach Behandlung maligner Erkrankungen bei Kindern.